DPH Stock Overview
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians.
Dechra Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£50.50|
|52 Week High||UK£55.25|
|52 Week Low||UK£31.32|
|1 Month Change||-1.17%|
|3 Month Change||-4.36%|
|1 Year Change||52.29%|
|3 Year Change||134.01%|
|5 Year Change||308.58%|
|Change since IPO||3,725.76%|
Recent News & Updates
It Looks Like Shareholders Would Probably Approve Dechra Pharmaceuticals PLC's (LON:DPH) CEO Compensation Package
It would be hard to discount the role that CEO Ian Page has played in delivering the impressive results at Dechra...
Dechra Pharmaceuticals' (LON:DPH) Upcoming Dividend Will Be Larger Than Last Year's
Dechra Pharmaceuticals PLC ( LON:DPH ) has announced that it will be increasing its dividend on the 19th of November to...
|DPH||GB Pharmaceuticals||GB Market|
Return vs Industry: DPH exceeded the UK Pharmaceuticals industry which returned 8.4% over the past year.
Return vs Market: DPH exceeded the UK Market which returned 10.9% over the past year.
|DPH Average Weekly Movement||4.3%|
|Pharmaceuticals Industry Average Movement||5.8%|
|Market Average Movement||4.9%|
|10% most volatile stocks in GB Market||9.8%|
|10% least volatile stocks in GB Market||2.6%|
Stable Share Price: DPH is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: DPH's weekly volatility (4%) has been stable over the past year.
About the Company
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies.
Dechra Pharmaceuticals Fundamentals Summary
|DPH fundamental statistics|
Is DPH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DPH income statement (TTM)|
|Cost of Revenue||UK£262.10m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Feb 21, 2022
|Earnings per share (EPS)||0.51|
|Net Profit Margin||9.13%|
How did DPH perform over the long term?See historical performance and comparison
0.8%Current Dividend Yield
Is Dechra Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: DPH (£50.5) is trading above our estimate of fair value (£37.03)
Significantly Below Fair Value: DPH is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: DPH is poor value based on its PE Ratio (98.6x) compared to the UK Pharmaceuticals industry average (30.3x).
PE vs Market: DPH is poor value based on its PE Ratio (98.6x) compared to the UK market (19x).
Price to Earnings Growth Ratio
PEG Ratio: DPH is poor value based on its PEG Ratio (6.4x)
Price to Book Ratio
PB vs Industry: DPH is overvalued based on its PB Ratio (8.6x) compared to the GB Pharmaceuticals industry average (4.5x).
How is Dechra Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DPH's forecast earnings growth (15.4% per year) is above the savings rate (0.9%).
Earnings vs Market: DPH's earnings (15.4% per year) are forecast to grow faster than the UK market (12.5% per year).
High Growth Earnings: DPH's earnings are forecast to grow, but not significantly.
Revenue vs Market: DPH's revenue (6.9% per year) is forecast to grow faster than the UK market (4.9% per year).
High Growth Revenue: DPH's revenue (6.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DPH's Return on Equity is forecast to be low in 3 years time (19.8%).
How has Dechra Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DPH has high quality earnings.
Growing Profit Margin: DPH's current net profit margins (9.1%) are higher than last year (6.6%).
Past Earnings Growth Analysis
Earnings Trend: DPH's earnings have grown by 18.2% per year over the past 5 years.
Accelerating Growth: DPH's earnings growth over the past year (63.7%) exceeds its 5-year average (18.2% per year).
Earnings vs Industry: DPH earnings growth over the past year (63.7%) exceeded the Pharmaceuticals industry -20.6%.
Return on Equity
High ROE: DPH's Return on Equity (8.8%) is considered low.
How is Dechra Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: DPH's short term assets (£392.2M) exceed its short term liabilities (£155.8M).
Long Term Liabilities: DPH's short term assets (£392.2M) do not cover its long term liabilities (£425.4M).
Debt to Equity History and Analysis
Debt Level: DPH's net debt to equity ratio (29.1%) is considered satisfactory.
Reducing Debt: DPH's debt to equity ratio has reduced from 56.4% to 47.8% over the past 5 years.
Debt Coverage: DPH's debt is well covered by operating cash flow (29.4%).
Interest Coverage: DPH's interest payments on its debt are well covered by EBIT (9.9x coverage).
What is Dechra Pharmaceuticals's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: DPH's dividend (0.8%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (1.38%).
High Dividend: DPH's dividend (0.8%) is low compared to the top 25% of dividend payers in the UK market (4.17%).
Stability and Growth of Payments
Stable Dividend: DPH's dividends per share have been stable in the past 10 years.
Growing Dividend: DPH is not paying a notable dividend for the UK market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: DPH is not paying a notable dividend for the UK market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DPH's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ian Page (60 yo)
Mr. Ian D. Page has been the Chief Executive Officer and Managing Director of Dechra Pharmaceuticals Plc since November 2001 and 1998 respectively and also serves as its Executive Director since 1997. Mr....
CEO Compensation Analysis
Compensation vs Market: Ian's total compensation ($USD3.49M) is above average for companies of similar size in the UK market ($USD2.16M).
Compensation vs Earnings: Ian's compensation has increased by more than 20% in the past year.
Experienced Management: DPH's management team is considered experienced (4.4 years average tenure).
Experienced Board: DPH's board of directors are considered experienced (5.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: DPH insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Dechra Pharmaceuticals PLC's employee growth, exchange listings and data sources
- Name: Dechra Pharmaceuticals PLC
- Ticker: DPH
- Exchange: LSE
- Founded: 1997
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£5.466b
- Shares outstanding: 108.35m
- Website: https://www.dechra.com
Number of Employees
- Dechra Pharmaceuticals PLC
- 24 Cheshire Avenue
- Cheshire Business Park
- CW9 7UA
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/12/01 21:52|
|End of Day Share Price||2021/12/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.